Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy

Harit Desai, Wilbert S. Aronow, Fausan S. Tsai, Chul Ahn, Hoang M. Lai, Harshad Amin, Kaushang Gandhi, William H. Frishman, Martin Cohen, Carmine Sorbera

Research output: Contribution to journalArticle

15 Scopus citations


Of 209 patients with heart failure treated with combined cardiac resynchronization therapy and implantable cardioverter-defibrillator therapy, appropriate cardioverter-defibrillator shocks occurred at 34-month follow-up in 22 of 121 patients (18%) on statins and in 30 of 88 patients (34%) not on statins (P =.009). Deaths occurred in 3 of 121 patients (2%) on statins and in 9 of 88 patients (10%) not on statins (P =.017). Stepwise Cox regression analysis showed that significant independent prognostic factors for appropriate shocks were use of statins (risk ratio = 0.46), smoking (risk ratio = 3.5), and diabetes (risk ratio = 0.34). Significant independent prognostic factors for the time to mortality were use of statins (risk ratio = 0.05), use of digoxin (risk ratio = 4.2), systemic hypertension (risk ratio = 14.2), diabetes (risk ratio = 4.3), and left ventricular ejection fraction (risk ratio = 1.1).

Original languageEnglish (US)
Pages (from-to)176-179
Number of pages4
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Issue number3
Publication statusPublished - Sep 2009



  • Cardiac resynchronization therapy
  • Cardioverter-defibrillator shocks
  • Heart failure
  • Statins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this